3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
23
Lymphoma
5
Recurrence
3
Hematologic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Immunoglobulin Light-chain Amyloidosis
1
Amyloidosis
1
Advanced Non-hematologic Malignancies
1
Interventions
miridesap
3
Dexamethasone
3
Cyclophosphamide
2
Bortezomib
2
venetoclax
1
ixazomib
1
daratumumab
1
birtamimab
1
belantamab mafodotin
1
Pharmaceutical Preparations
1
Lisaftoclax
1
GTP Cyclohydrolase
1
Drug Evaluation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Amyloidosis
×
ixazomib
×
Clear all
NCT02924272
2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2
Completed
32 enrolled
13 charts